Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)

<p>Abstract</p> <p>Background</p> <p>Intravesical Bacillus Calmette-Guerin (BCG) is an effective treatment for bladder superficial carcinoma and it is being tested in interstitial cystitis patients, but its precise mechanism of action remains poorly understood. It is no...

Full description

Bibliographic Details
Main Authors:	Centola Michael, Frank Mark, Knowlton Nicholas, Wallis Gemma, Davis Carole, Simpson Cindy, Saban Marcia R, Gallucci Randle M, Saban Ricardo
Format:	Article
Language:	English
Published:	BMC 2007-05-01
Series:	BMC Immunology
Online Access:	http://www.biomedcentral.com/1471-2172/8/6

Similar Items

Bacillus Calmette-Guérin Spondylodiscitis after Intravesical BCG Therapy: A Case Report
by: Akihito Kawai, et al.
Published: (2022-11-01)

Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer
by: Fernando Korkes, et al.
Published: (2021-02-01)

Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
by: Bedeir Ali-El-Dein, et al.
Published: (2013-01-01)

Poncet’s disease after the intravesical instillation of Bacillus Calmette–Guérin (BCG): a case report
by: Paula Cíntia Machado Sampaio, et al.
Published: (2017-08-01)

Bladder Contracture – A Rare and Serious Side Effect of Intravesical Bacillus Calmette-Guérin Therapy
by: Cindy Garcia, et al.
Published: (2016-01-01)

Interstitial pneumonitis secondary to intravesical bacillus calmette-guerin for carcinoma in-situ of the bladder
by: Eric K. Diner, et al.
Published: (2004-10-01)

Systemic bacillus Calmette-Guérin (BCG) infection and accompanying warm autoimmune haemolytic anaemia following intravesical BCG immunotherapy
by: Alper Tuna Güven, et al.
Published: (2023-08-01)

Bacillus Calmette-Guerin (BCG): the adroit vaccine
by: Oluwafolajimi A. Adesanya, et al.
Published: (2021-02-01)

Sporotrichoid distributed tuberculous panniculitis as a late complication of intravesical bacillus Calmette–Guérin (BCG) immunotherapy
by: Nina Nielens, et al.
Published: (2022-04-01)

Intravesical bacillus Calmette-Guerin for bladder cancer: What is known? What is not? What is next?
by: Khaled Madbouly
Published: (2013-01-01)

Granulomatous Prostatitis Associated with Intravesical Bacillus Calmette Guerin Therapy
by: Elif Gündoğdu
Published: (2024-02-01)

Mycobacterium bovis infection of a femorofemoral bypass graft following intravesical Bacillus Calmette–Guérin (BCG) immunotherapy
by: Ryan K. Meyer, M.D., et al.
Published: (2020-05-01)

Reiter’s syndrome following intravesical Bacillus Calmette-Guerin therapy for bladder carcinoma: Case report
by: Hajar Aown Allah Alsulami, et al.
Published: (2023-01-01)

PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette–Guérin (BCG) Therapy
by: Moritz Maas, et al.
Published: (2024-03-01)

Bacillus Calmette–Guérin and Bladder Cancer
by: Azad H.A. Razack
Published: (2007-10-01)

Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
by: Christopher James, et al.
Published: (2023-04-01)

Tuberculous prostatic abscess following intravesical bacillus Calmette-Guérin immunotherapy
by: Bin Wang, et al.
Published: (2019-09-01)

Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity
by: Thiru Prasanna, et al.
Published: (2017-11-01)

Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer—analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I)
by: Yuvaraja B. Thyavihally, et al.
Published: (2022-04-01)

Drug‐induced interstitial pneumonia after intravesical Bacillus Calmette‐Guerin administration for bladder cancer with scleroderma
by: Fumie Yoshioka, et al.
Published: (2023-03-01)

Bacillus Calmette–Guerin intravesical instillation therapy-induced urothelial necrosis of the bladder and upper urinary tract
by: Tsubasa Kondo, et al.
Published: (2022-09-01)

Is bladder tumor location associated with prostate cancer detection after intravesical bacillus Calmette-Guérin instillation?
by: Sungwoo Hong, et al.
Published: (2014-01-01)

Disseminated Bacillus Calmette-Guérin (BCG) infections in infants with immunodeficiency
by: Suleiman Al-Hammadi, et al.
Published: (2017-05-01)

Bacillus Calmette-Guérin (BCG) therapy lowers the incidence of Alzheimer's disease in bladder cancer patients.
by: Ofer N Gofrit, et al.
Published: (2019-01-01)

Intravesical bacillus Calmette - Guérin (BCG) in treating non-muscle invasive bladder cancer (NMIBC)- Analysis of adverse effects and effectiveness between two strains of BCG (Danish 1331 and Moscow)
by: V. Agarwal, et al.
Published: (2020-11-01)

Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome
by: R. Waked, et al.
Published: (2020-05-01)

Is intravesical bacillus Calmette-Guerin safe and efficacious in steroid treated and immunocompromized patients
by: Santosh Kumar, et al.
Published: (2006-01-01)

A severe complication of intravesical bacillus Calmette-Guerin: An effect of different strains
by: Li Sian Low, et al.
Published: (2021-05-01)

New-onset guttate psoriasis following intravesical immunotherapy of Bacillus Calmette–Guerin
by: Chih-Tsung Hung, et al.
Published: (2012-09-01)

Case report: Mycobacterium bovis orchitis post intravesical Bacillus Calmette Guerin
by: Mohammed Samannodi, et al.
Published: (2018-01-01)

Successful treatment with low‐dose oral steroids for contracted bladder after intravesical instillation of Bacillus Calmette–Guérin
by: Akinobu Katami, et al.
Published: (2024-03-01)

Role of Aspirin in Patients with Bladder Cancer Receiving Intravesical Bacillus Calmette-Guerin: A Prospective, Observational Study
by: Rupesh Gupta, et al.
Published: (2017-10-01)

Efficacy and toxicity of intravesical Bacillus Calmette-Guérin therapy in elderly patients with non-muscle-invasive bladder cancer
by: Yuki Matsuoka, et al.
Published: (2021-03-01)

Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure
by: Govind Shantharam, et al.
Published: (2021-03-01)

The impact of Bacillus Calmette-Guérin (BCG) vaccination on the course of COVID-19
by: Jakub Krzysztof Gałązka
Published: (2022-10-01)

Tuberculous epididymo-orchitis secondary to Bacillus Calmette-Guérin (BCG) in non-muscular invasive bladder cancer
by: Luis Felipe Lara Moscoloni, et al.
Published: (2021-07-01)

Secondary Haemophagocytic Lymphohistiocytosis Syndrome (HLH) After Intravesical Instillation of Bacillus Calmette-Guérin (BCG): A Case Report and Review of the Literature
by: Konstantinos Manganas, et al.
Published: (2022-10-01)

Bacillus Calmette-Guerin in the management of superficial bladder cancer
by: Rakesh Kapoor, et al.
Published: (2008-01-01)

Outcomes of intravesical Bacillus Calmette-Guerin in patients with non-muscle invasive bladder cancer: a retrospective study in Australia
by: Chamodi Pillippu Hewa, et al.
Published: (2024-02-01)

Tuberculous Granuloma in the Scrotal Skin After Intravesical Bacillus Calmette-Guerin Therapy for Bladder Cancer: A Case Report
by: Hiroshi Shimura, et al.
Published: (2017-02-01)